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Purpose of the study
This study aimed at testing the immuno-virological
response in 20 consecutive HIV-1 infected patients treated
with darunavir (DRV) within the early access program
through 12 months of therapy. Evolution of drug resist-
ance on HIV-RNA, on proviral DNA and proviral DNA
quantification at different time points were carried out.
Methods
20 virologically multifailed subjects received a new
HAART regimen composed by two NRTI and DRV as
boosted PI; 16/20 were under T20 treatment. Immuno-
virological response was determined through CD4+ cell
counts and viral load (VL) detection. Genotypic analysis
on HIV-RNA was performed from plasma samples at the
baseline (BL) and on proviral DNA from PBMCs at differ-
ent time points: BL, week 4, 12, 24, 36 and 48. HIV-RNA
was extracted from patients with HIV-RNA >400 copies/
mL and processed by RT-PCR. Nested-PCR for all samples
was carried out in order to sequence pol and env gene,
proviral DNA was quantified by real-time PCR.
Summary of results
Immune-virological status at BL showed a mean value of
248 CD4+ cells/μL and a viral load of 3.9 log10. After 12
months of therapy, we observed an increase in CD4+
count of 164 cells/μL and a decrease in HIV-RNA of 1.9
log10. We analyzed RNA mutations at BL in 13/20
patients and 11/13 showed the presence of at least one
DRV mutation. The two most frequent DRV mutations
were L33F (54%) and I84V (31%). BL proviral DNA
showed changes in 7/20 patients. In 2/7, some mutations
detected in RNA at BL mirrored in proviral DNA after one
month of therapy. Mutational pattern at BL was more rep-
resented on HIV-RNA than on proviral DNA since the
mean DRV mutational score was 4.4 for the former and
2.7 for the latter. During follow-up, 4/20 patients showed
a progressive decrease of the DRV mutation number in the
pro gene. After 12 months of treatment, all these subjects
reverted to wild-type. On the contrary, restoration to a
wild-type status did not occur in RT. No new mutation
appeared on the env gene. Patients with high HIV-RNA at
BL showed high levels in proviral DNA at the end of
observation, whereas responders behaved in the opposite
way.
Conclusion
We demonstrated that the immune-virological response
during a DRV-including therapy was optimal in the
majority of enrolled subjects. The decrease in the number
of mutations during therapy is likely due to a reduced
capacity in the DNA proviral integration under drug pres-
sure and this might be confirmed by the proviral DNA
quantification.
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